Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer

• Status: Unknown status
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

In extrahepatic bile duct cancer and pancreatic cancer, we will treat postoperatively with COX2 inhibitor and assess survival rate and recurrent rate.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Seoul National University Bundang Hospital
• Treatments: Celecoxib; Cyclooxygenase 2 Inhibitors; Pancreatin; Pancrelipase

Criteria

Inclusion Criteria:

• The patients who underwent operation for extrahepatic bile duct cancer or pancreas cancer

• Between 19 and 70 years old

• Agreed to consent sheet

Exclusion Criteria:

• The patients cannot administration of drug due to severe postoperative morbidities.

• Preexisting heart disease: Ischemic heart disease, Heart failure. Severe uncontrolled hypertension (systolic BP>160)

• Renal insufficiency: CCR < 50 or serum creatinin >3.0

• Hepatic insufficiency: Liver cirrhosis or active hepatitis

• Preexisting allergic reaction history for NSAIDs or Sulfonamide

• Current drug intake: Warfarin. Lithium, Fluconazole, Aspirin, Celecoxib

• Preexisting Asthma. Especially aspirin-sensitive asthma.

• Contraindications to aspirin, clopidogrel or celecoxib

• When patients refused

• Patients has psychological problem